MX2009001292A - Anticuerpos modificadores de enfermedad cancerosa. - Google Patents

Anticuerpos modificadores de enfermedad cancerosa.

Info

Publication number
MX2009001292A
MX2009001292A MX2009001292A MX2009001292A MX2009001292A MX 2009001292 A MX2009001292 A MX 2009001292A MX 2009001292 A MX2009001292 A MX 2009001292A MX 2009001292 A MX2009001292 A MX 2009001292A MX 2009001292 A MX2009001292 A MX 2009001292A
Authority
MX
Mexico
Prior art keywords
antibodies
cancer
disease modifying
cancerous disease
modifying antibodies
Prior art date
Application number
MX2009001292A
Other languages
English (en)
Inventor
Helen P Findlay
Susan E Hahn
David S F Young
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2009001292A publication Critical patent/MX2009001292A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un método para producir anticuerpos modificadores de enfermedad cancerosa en un paciente usando un novedoso paradigma de detección. Mediante la segregación de los anticuerpos anticancerosos usando citotoxicidad de células de cáncer como objetivo, el proceso hace posible la producción de anticuerpos anticancerosos para propósitos terapéuticos y de diagnóstico. Los anticuerpos pueden utilizarse como auxiliares para determinar la fase y para el diagnóstico de un cáncer, y se pueden utilizar para tratar tumores primarios, por ejemplo tumores cancerosos de próstata o de mama y metástasis tumoral. Los anticuerpos anticancerosos pueden ser conjugados con toxinas, enzimas, compuestos radiactivos, y células hematógenas.
MX2009001292A 2006-08-03 2006-11-17 Anticuerpos modificadores de enfermedad cancerosa. MX2009001292A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/462,092 US7175846B2 (en) 2003-01-21 2006-08-03 Cancerous disease modifying antibodies
PCT/CA2006/001879 WO2008014583A1 (en) 2006-08-03 2006-11-17 Cancerous disease modifying antibodies

Publications (1)

Publication Number Publication Date
MX2009001292A true MX2009001292A (es) 2009-09-15

Family

ID=38996806

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001292A MX2009001292A (es) 2006-08-03 2006-11-17 Anticuerpos modificadores de enfermedad cancerosa.

Country Status (10)

Country Link
US (1) US7175846B2 (es)
EP (1) EP2046381A4 (es)
JP (1) JP2009545533A (es)
KR (1) KR20090047448A (es)
CN (1) CN101534857A (es)
AU (1) AU2006346988A1 (es)
BR (1) BRPI0621921A2 (es)
CA (1) CA2658504A1 (es)
MX (1) MX2009001292A (es)
WO (1) WO2008014583A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7009040B2 (en) * 2003-01-21 2006-03-07 Arius Research, Inc. Cancerous disease modifying antibodies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828991A (en) * 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
NZ222509A (en) * 1986-11-19 1993-03-26 Oncogen Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
US4861581A (en) * 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5171665A (en) * 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
DE69229254T2 (de) * 1991-10-30 1999-09-23 Idemitsu Kosan Co Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper
IL105008A0 (en) * 1992-03-13 1993-07-08 Yeda Res & Dev Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis
CA2154266A1 (en) * 1993-02-05 1994-08-18 John F. Codington Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
JPH10505819A (ja) * 1994-06-24 1998-06-09 ヴラディミール ピー． トーチリン 腫瘍の治療及び予防のための自己抗体の使用方法
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US20040105816A1 (en) * 1999-10-08 2004-06-03 Young David S. F. Cancerous disease modifying antibodies
US6180357B1 (en) * 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
US7431923B2 (en) * 2005-01-03 2008-10-07 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7534429B2 (en) * 2000-11-29 2009-05-19 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7009040B2 (en) * 2003-01-21 2006-03-07 Arius Research, Inc. Cancerous disease modifying antibodies
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7361342B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cancerous disease modifying antibodies
US20060216235A1 (en) * 2003-01-21 2006-09-28 Young David S F Cancerous disease modifying antibodies
US7488475B2 (en) * 2003-01-21 2009-02-10 Arius Research, Inc. Antibody therapy of tumors

Also Published As

Publication number Publication date
AU2006346988A1 (en) 2008-02-07
CN101534857A (zh) 2009-09-16
US7175846B2 (en) 2007-02-13
CA2658504A1 (en) 2008-02-07
KR20090047448A (ko) 2009-05-12
WO2008014583A1 (en) 2008-02-07
EP2046381A1 (en) 2009-04-15
EP2046381A4 (en) 2010-07-21
JP2009545533A (ja) 2009-12-24
BRPI0621921A2 (pt) 2011-12-20
US20060263372A1 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
EP1718737A4 (en) ANTIBODIES MODIFYING CANCER DISEASES
WO2007095749A8 (en) Cytotoxicity mediation of cells evidencing surface expression of trop-2
MX2009007619A (es) Anticuerpos modificadores de una enfermedad cancerigena.
CY1106455T1 (el) Τροποποιητικα αντισωματα καρκινικης νοσου
MX2009001015A (es) Anticuerpos modificadores de enfermedad cancerosa.
WO2004065422A3 (en) Cancerous disease modifying antibodies
MX2009007618A (es) Anticuerpos modificadores de una enfermedad cancerigena.
MX2009007617A (es) Anticuerpos modificadores de una enfermedad cancerigena.
WO2005012361A3 (en) Antibodies raised against colon carcinomas
WO2003086456A3 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
MX2009001292A (es) Anticuerpos modificadores de enfermedad cancerosa.
MX2009011667A (es) Anticuerpos de modificacion de enfermedad cancerosa.
MX336476B (es) Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado.
EP1929034A4 (en) ANTIBODIES CAPABLE OF MODIFYING EVOLUTION OF CANCER DISEASE
GB0718878D0 (en) Photodynamic Theraphy and diagnosis
MX2009009919A (es) Anticuerpo 010207-01 modificador de la enfermedad del cancer, producido por la linea celular ar51a630.3 del hibridoma.
WO2008058380A8 (en) Cancerous disease modifying antibodies
NO20091459L (no) Cancerose sykdomsmodifiserende antistoffer
BRPI0718609A8 (pt) Anticorpos modificadores de doença cancerosa.
DK1360208T3 (da) Fremgangsmåde til fremstilling af cytotoksiske anticancer-antistoffer
AR070279A1 (es) Anticuerpos modificadores de enfermedades cancerosas (cdma)
AR072750A1 (es) Anticuerpos modificadores de enfermedades cancerosas
AR070280A1 (es) Anticuerpos monoclonales modificadores de enfermedades cancerosas (cdmab)
AR071847A1 (es) Anticuerpos monoclonales modificadores de enfermedades cancerosas
WO2009094751A8 (en) An anti-cancer cytotoxic monoclonal antibody

Legal Events

Date Code Title Description
FA Abandonment or withdrawal